A Phase 2 interventional study of Nebivolol and Diltiazem in Myocardial Bridging, sponsored by Stanford University. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Stanford University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The proposed clinical trial is relevant to public health because it is expected to expand the differential diagnosis and provide an evidence--based therapy for the large population of patients with angina in the absence of obstructive CAD who currently remain undiagnosed and untreated. It, therefore, upholds an important part of the mission of the The National Heart, Lung, and Blood Institute (NHLBI), which is to promote the treatment of heart disease and enhance the health of all individuals so that they can live longer and more fulfilling lives.
Angina in the absence of obstructive coronary artery disease (CAD) affects millions, resulting in a reduced quality of life and a burden on the health care system. Previous work has focused on endothelial and microvascular dysfunction as causes of angina in these patients, but even when these etiologies are tested for, nearly half of patients remain undiagnosed, and proven therapies are lacking. The long--term goal of this research proposal is to improve the lives of patients with angina in the absence of obstructive CAD. These patients have been found to have a disproportionate prevalence of myocardial bridges (MBs) (60% vs. 30% in the general population).
MBs are known to cause angina, and the mechanism by which they do so is also known, but MBs have not been actively studied in the context of patients with angina in the absence of obstructive CAD. Medical therapies for symptomatic MBs, including beta blockers and calcium channel blocker have been suggested, but have never been appropriately tested, and may not be better than placebo. The overall objective of this research proposal is to demonstrate that MBs are an important and treatable cause of angina in patients with non--obstructive CAD.
The investigator will conduct the first--ever randomized, double--blind, placebo--controlled trial of medical therapy in patients with angina and an MB. The rationale is that a proven treatment would significantly expand the paradigm by which patients with angina in the absence of obstructive CAD are evaluated and treated. Our central hypothesis is that beta blockers and calcium channel blockers are effective treatments for reducing angina in patients with an MB compared with placebo. Guided by strong preliminary data, this hypothesis will be tested by pursuing two specific aims: 1) Determine the efficacy of beta blockers and calcium channel blockers in treating patients with angina and an MB and 2) Identify predictors of efficacy of beta blockers and calcium channel blockers in treating patients with angina and an MB. For Aim #1, the investigator will randomize a total of 360 adult patients with angina and an MB into one of three treatment arms: beta blocker (nebivolol), calcium channel blocker (diltiazem), or placebo (1:1:1).
Efficacy will be determined after 30 days on the study drug by a change in angina, as assessed by the Seattle Angina Questionnaire (SAQ). The investigator will also evaluate changes in exercise capacity, as well as drug adherence and side effects. For Aim #2, the investigator will evaluate MB muscle index (MMI, a product of MB length x depth) by coronary computed tomography angiography, as well as male sex, as predictors of efficacy. Randomization will be stratified on sex, ensuring a balance of women and men in each arm. The proposed research is innovative because it shifts the current clinical perspective on angina in the absence of obstructive CAD by considering myocardial bridging as a potential etiology.
It is also significant because it will substantially increase the number of patients with angina in the absence of obstructive CAD that clinicians are able to diagnose and treat, ultimately leading to improvements in quality of life and a reduction in health care costs.
Stanford University is the lead sponsor of 2,173 studies on the registry; 433 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nebivolol
Drug: Diltiazem
Other: Placebo
The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
Change in Angina Score Assessed by the Seattle Angina Questionnaire (SAQ)
Effectiveness of beta blockers and calcium channel blockers for reducing angina in patients with a Myocardial Bridge (MB) compared to placebo determined after 30 days on the study drug by a change in angina, as assessed by the Seattle Angina Questionnaire (SAQ). The SAQ assesses 5 domains: physical limitation, angina stability angina frequency, treatment satisfaction, and quality of life. Each domain score is normalized to a range of 0 to 100, with higher scores corresponding to better outcomes.
Time frame: baseline and 30 days
Duke Treadmill Score by Risk Category
Changes in exercise capacity will be measured by difference in exercise time increment between the groups. The Duke treadmill score is calculated as exercise time × (5 × ST-segment deviation) - (4 × exercise angina), with 0 = no angina, 1 = non-limiting angina, and 2 = exercise-limiting angina. Possible scores range from -25 (highest risk) to +15 (lowest risk). Scores are reported by the number of participants in each risk category: low risk (≥+5), moderate risk (-10 to +4) and high risk (≤-11) (Shaw, et al, 1998).
Time frame: baseline, 30 days
Duke Treadmill Score
The Duke treadmill score is calculated as exercise time × (5 × ST-segment deviation) - (4 × exercise angina), with 0 = no angina, 1 = non-limiting angina, and 2 = exercise-limiting angina. Possible scores range from -25 (highest risk) to +15 (lowest risk).
Time frame: baseline, 30 days
Number of Participants With Cardiac Events
Major adverse cardiovascular events include death, heart attack, coronary stent or bypass surgery, and stroke.
Time frame: 30 days, 6 months
Drug Adherence.
Percentage of drug taken by participants, measured by pill count at the end of 30 days.
Time frame: 30 days
Number of Participants With Side Effects
Patient self-reported side effects recorded in a diary to be turned in at 30 days. In addition, patients are requested to contact us regarding any serious side effects during the study. Finally, patients are asked about any side effects they experienced during their 30-day follow-up to ensure that symptoms are captured.
Time frame: 30 days
Treatment Course
Number of participants who stayed on the study drug at the initial dose, stayed on the study drug at a different dose, switched to an alternate therapy, and/or underwent further cardiac testing.
Time frame: 6 months
| Milestone | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo |
|---|---|---|---|
| Started | 2 | 1 | 2 |
| Had at least 1 post-baseline visit | 2 | 1 | 1 |
| Completed | 2 | 1 | 1 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
Effectiveness of beta blockers and calcium channel blockers for reducing angina in patients with a Myocardial Bridge (MB) compared to placebo determined after 30 days on the study drug by a change in angina, as assessed by the Seattle Angina Questionnaire (SAQ). The SAQ assesses 5 domains: physical limitation, angina stability angina frequency, treatment satisfaction, and quality of life. Each domain score is normalized to a range of 0 to 100, with higher scores corresponding to better outcomes.
| score on a scale | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo |
|---|---|---|---|
| Physical limitation - baseline | 44.4 ± 24.4 | 62.2 ± NA | 53.4 ± 15.6 |
| Physical limitation - 30 days | 53.6 ± 24.5 | 68.0 ± NA | 17.8 ± NA |
| Angina stability - baseline | 40 ± 0 | 40 ± NA | 80 ± 20 |
| Angina stability - 30 days | 50 ± 30 | 60 ± NA | 20 ± 0 |
| Angina frequency - baseline | 70 ± 0 | 60 ± NA | 75 ± 25 |
| Angina frequency - 30 days | 80 ± 10 | 80 ± NA | 30 ± NA |
| Treatment satisfaction - baseline | 67.7 ± 8.9 | 100 ± NA | 76.5 ± 5.85 |
| Treatment satisfaction - 30 days | 64.7 ± 11.8 | 94.1 ± NA | 29.4 ± NA |
| Quality of life - baseline | 41.6 ± 25 | 41.7 ± NA | 37.5 ± 20.9 |
| Quality of life - 30 days | 54.1 ± 20.9 | 58.3 ± NA | 25 ± NA |
Changes in exercise capacity will be measured by difference in exercise time increment between the groups. The Duke treadmill score is calculated as exercise time × (5 × ST-segment deviation) - (4 × exercise angina), with 0 = no angina, 1 = non-limiting angina, and 2 = exercise-limiting angina. Possible scores range from -25 (highest risk) to +15 (lowest risk). Scores are reported by the number of participants in each risk category: low risk (≥+5), moderate risk (-10 to +4) and high risk (≤-11) (Shaw, et al, 1998).
| Participants | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo |
|---|---|---|---|
| Low risk - baseline | 0 | 0 | 0 |
| Moderate risk - baseline | 2 | 1 | 2 |
| High risk - baseline | 0 | 0 | 0 |
| Low risk - 30 days | 0 | 1 | 0 |
| Moderate risk - 30 days | 1 | 0 | 0 |
| High risk - 30 days | 0 | 0 | 1 |
The Duke treadmill score is calculated as exercise time × (5 × ST-segment deviation) - (4 × exercise angina), with 0 = no angina, 1 = non-limiting angina, and 2 = exercise-limiting angina. Possible scores range from -25 (highest risk) to +15 (lowest risk).
| score on a scale | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo |
|---|---|---|---|
| Baseline | 2.3 ± 2.35 | 3.0 ± NA | 1.5 ± 4.95 |
| 30 days | 2 ± NA | 10 ± NA | -11 ± NA |
Major adverse cardiovascular events include death, heart attack, coronary stent or bypass surgery, and stroke.
| Participants | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo |
|---|---|---|---|
| 30 days | 0 | 0 | 0 |
| 6 months | 0 | 0 | 0 |
Percentage of drug taken by participants, measured by pill count at the end of 30 days.
| percentage of drug taken | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo |
|---|---|---|---|
| Drug Adherence. | 99.5 ± 0.5 | 100 ± NA | 100 ± NA |
Patient self-reported side effects recorded in a diary to be turned in at 30 days. In addition, patients are requested to contact us regarding any serious side effects during the study. Finally, patients are asked about any side effects they experienced during their 30-day follow-up to ensure that symptoms are captured.
| Participants | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo |
|---|---|---|---|
| Number of Participants With Side Effects | 0 | 0 | 0 |
Number of participants who stayed on the study drug at the initial dose, stayed on the study drug at a different dose, switched to an alternate therapy, and/or underwent further cardiac testing.
| Participants | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo |
|---|---|---|---|
| Stayed on study drug at the initial dose | 2 | 0 | 0 |
| Stayed on study drug at a different dose | 0 | 1 | 0 |
| Switched to alternate therapy | 0 | 0 | 1 |
| Underwent further cardiac testing | 0 | 0 | 0 |
Collected over Up to 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Beta Blocker (Nebivolol) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Calcium Channel Blocker (Diltiazem) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Placebo | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Age, Categorical(Participants) | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 1 | 2 | 5 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo | Total |
|---|---|---|---|---|
| Female | 2 | 0 | 1 | 3 |
| Male | 0 | 1 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 1 | 2 | 4 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo | Total |
|---|---|---|---|---|
| Asian | 0 | 0 | 2 | 2 |
| White | 1 | 0 | 0 | 1 |
| Other | 1 | 1 | 0 | 2 |
| Region of Enrollment(Participants) | Beta Blocker (Nebivolol) | Calcium Channel Blocker (Diltiazem) | Placebo | Total |
|---|---|---|---|---|
| United States | 2 | 1 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Mar 2022, 16 months.
Results were first posted in Feb 2025, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nebivolol · Diltiazem
Myocardial Bridging